| 赵丽娟,武建军,云宇婷,张春凤,娜日格乐.荆花胃康胶丸联合标准四联疗法对Hp相关十二指肠溃疡患者血清肽类胃肠激素、胃蛋白酶原和炎症介质的影响[J].,2022,(17):3314-3318 |
| 荆花胃康胶丸联合标准四联疗法对Hp相关十二指肠溃疡患者血清肽类胃肠激素、胃蛋白酶原和炎症介质的影响 |
| Effects of Jinghuaweikang Capsule Combined with Standard Quadruple Therapy on Serum Peptide Gastrointestinal Hormones, Pepsinogen and Inflammatory Mediators in Patients with Hp Related Duodenal Ulcer |
| 投稿时间：2022-02-27 修订日期：2022-03-23 |
| DOI：10.13241/j.cnki.pmb.2022.17.022 |
| 中文关键词: 荆花胃康胶丸 标准四联疗法 幽门螺杆菌相关十二指肠溃疡 肽类胃肠激素 胃蛋白酶原 炎症介质 |
| 英文关键词: Jinghuaweikang capsule Standard quadruple therapy Helicobacter pylori-related duodenal ulcer Peptide gastrointestinal hormones Pepsinogen Inflammatory mediators |
| 基金项目:内蒙古自治区自然科学基金项目（2020MS08153） |
|
| 摘要点击次数: 469 |
| 全文下载次数: 196 |
| 中文摘要: |
| 摘要 目的：探讨荆花胃康胶丸联合标准四联疗法对幽门螺杆菌（Hp）相关十二指肠溃疡（DU）患者血清肽类胃肠激素、胃蛋白酶原和炎症介质的影响。方法：选择2019年3月~2021年11月期间我院收治的Hp相关DU患者103例。按随机数字表法，将其分为对照组（标准四联疗法治疗，51例）和联合组（荆花胃康胶丸联合标准四联疗法治疗，52例）。对比两组疗效、Hp清除率、血清肽类胃肠激素[胃泌素（GAS）、胃动素（MTL）、 生长抑素（SS）和降钙素基因相关肽（CGRP）]、胃蛋白酶原[胃蛋白酶原Ⅰ（PGⅠ）、胃蛋白酶原Ⅱ（PGⅡ）]和炎症介质[白介素-8（IL-8）、白介素-1β（IL-1β）、转化生长因子β1（TGF-β1）]，统计两组用药安全性。结果：联合组的临床总有效率、Hp清除率高于对照组（P<0.05）。两组治疗后血清IL-8、IL-1β、TGF-β1、PGⅠ、PGⅡ、GAS、MTL水平均下降，且联合组的下降程度大于对照组（P<0.05）。两组治疗后SS、CGRP均升高，且联合组的升高程度大于对照组（P<0.05）。两组不良反应发生率组间对比未见显著差异（P>0.05）。结论：荆花胃康胶丸联合标准四联疗法可通过提高Hp清除率、改善Hp相关DU患者的血清肽类胃肠激素、胃蛋白酶原和炎症介质水平，来进一步提高临床疗效。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effects of Jinghuaweikang capsule combined with standard quadruple therapy on serum peptide gastrointestinal hormones, pepsinogen and inflammatory mediators in patients with Helicobacter pylori (Hp) - related duodenal ulcer (DU). Methods: 103 patients with Hp-related DU treated in our hospital from March 2019 to November 2021 were selected. According to the random number table method, they were divided into control group (treated with standard quadruple therapy, 51 cases) and combined group (treated with Jinghuaweikang capsule combined with standard quadruple therapy, 52 cases). The efficacy, Hp clearance rate, serum peptide gastrointestinal hormones [gastrin (GAS), motilin (MTL), somatostatin (SS) and calcitonin gene-related peptide (CGRP)], pepsinogen [pepsinogen Ⅰ (PG Ⅰ), pepsinogen Ⅱ (PG Ⅱ)] and inflammatory mediators [interleukin-8 (IL-8), interleukin-1β (IL-1β) and transforming growth factor β1(TGF-β1)] were compared between the two groups, the drug safety of the two groups was counted. Results: The total clinical effective rate and Hp clearance rate of the combined group were higher than those of the control group (P<0.05). After treatment, serum levels of IL-8, IL-1β, TGF-β1, PG Ⅰ, PG Ⅱ, GAS and MTL in two groups decreased, and the decrease degree in combined group was greater than that in control group (P<0.05). SS and CGRP increased in two groups after treatment, and the increase degree in the combined group was greater than that in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: Jinghua Weikang capsule combined with standard quadruple therapy can further improve the clinical efficacy by increasing Hp clearance rate and improving the levels of serum peptide gastrointestinal hormones, pepsinogen and inflammatory mediators in patients with Hp-related DU. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
